Table 1.
Frailty category changes, therapeutic responses, and treatment discontinuation
| All, N (%) | Fit, N (%) | Intermediate fit, N (%) | Frail, N (%) | |
|---|---|---|---|---|
| Frailty category change | (N = 75) | (N = 30) | (N = 15) | (N = 30) |
| At least once | 28 (37.3) | 8 (26.7) | 5 (33.3) | 15 (50.0)a |
| At analysis | ||||
| Improved | 17 (22.7) | − | 2 (13.3) | 15 (50.0) |
| Deteriorated | 8 (10.7) | 6 (20.0) | 2 (13.3) | − |
| Response | (N = 74) | (N = 30) | (N = 14) | (N = 30) |
| ORR | 65 (87.8) | 30 (100) | 13 (92.9) | 22 (73.3) |
| CR or sCR | 40 (54.1) | 18 (60.0) | 9 (64.3) | 13 (43.3) |
| VGPR | 15 (20.3) | 8 (26.7) | 3 (21.4) | 4 (13.3) |
| PR | 10 (13.5) | 4 (13.3) | 1 (7.1) | 5 (16.7) |
| MR | 4 (5.4) | 0 (0) | 1 (7.1) | 3 (10.0) |
| SD | 5 (6.8) | 0 (0) | 0 (0) | 5 (16.7) |
| Reason for TD | (N = 90) | (N = 33) | (N = 16) | (N = 41) |
| Non-hematologic AE, any | 17 (18.9) | 5 (15.2) | 1 (6.3) | 11 (26.8) |
| Grade 2 | ||||
| PNP-P | 2 (2.2) | 2 (6.1) | − | − |
| Grade 3 | ||||
| Pneumonia | 1 (1.1) | − | − | 1 (2.4) |
| Cerebral infarction | 1 (1.1) | − | − | 1 (2.4) |
| Grade 4 | ||||
| Pneumonia | 5 (5.6) | 1 (3.0) | − | 4 (9.8) |
| Sepsis | 4 (4.4) | 1 (3.0) | − | 3 (7.3) |
| Acute heart failure | 1 (1.1) | 1 (3.0) | − | − |
| Intercurrent death | ||||
| Sudden death | 2 (2.2) | − | 1 (6.3) | 1 (2.4) |
| Acute renal failure | 1 (1.1) | − | − | 1 (2.4) |
| Hematologic AE | ||||
| Thrombocytopenia | 1 (1.1) | − | − | 1 (2.4)b |
| Reason other than AE, any | 16 (17.8) | 5 (15.2) | 3 (18.8) | 8 (19.5) |
| Deteriorating condition | 4 (4.4) | − | 1 (6.3) | 3 (7.3) |
| Disease progression | 3 (3.3) | 1 (3.0) | 1 (6.3) | 1 (2.4) |
| Noncompliance | 6 (6.7) | 2 (6.1) | 1 (6.3) | 3 (7.3) |
| COVID-19 | 3 (3.3) | 2 (6.1) | − | 1 (2.4) |
Abbreviations: ORR, overall response rate; sCR, stringent complete response; CR, complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PFS, progression-free survival; OS, overall response; TD, treatment discontinuation; AE, adverse event; PNP-P, peripheral neuropathy grade 2 with pain.
aIncluding four patients with age > 80 years.
bTD because of cerebral hemorrhage secondary to thrombocytopenia.